Pegaspargase
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00059 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 100 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | precursor lymphoblastic lymphoma/leukemia | KG + DL |
| 2 | chronic lymphocytic leukemia/small lymphocytic lymphoma with immunoglobulin heavy chain variable-region gene somatic hypermutation | KG + DL |
| 3 | pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma | KG + DL |
| 4 | follicular lymphoma | KG + DL |
| 5 | acute lymphoblastic leukemia | KG + DL |
| 6 | methylcobalamin deficiency type cblE | KG + DL |
| 7 | lymphoid neoplasm | KG + DL |
| 8 | Hodgkins lymphoma | KG + DL |
| 9 | chronic lymphocytic leukemia/small lymphocytic lymphoma | KG + DL |
| 10 | blast phase chronic myelogenous leukemia, BCR-ABL1 positive | KG + DL |
| 11 | myeloid leukemia | KG + DL |
| 12 | bladder transitional cell carcinoma | KG + DL |
| 13 | Quinquaud’s folliculitis decalvans | KG + DL |
| 14 | alopecia mucinosa | KG + DL |
| 15 | telogen effluvium | KG + DL |
| 16 | hereditary hypotrichosis with recurrent skin vesicles | KG + DL |
| 17 | alopecia antibody deficiency | KG + DL |
| 18 | alopecia-intellectual disability-hypergonadotropic hypogonadism syndrome | KG + DL |
| 19 | alopecia areata | KG + DL |
| 20 | lymphoblastic leukemia, acute, with lymphomatous features | KG + DL |
| 21 | mantle cell lymphoma | KG + DL |
| 22 | MALT lymphoma | KG + DL |
| 23 | neoplasm of immature B and T cells | KG + DL |
| 24 | Richter syndrome | KG + DL |
| 25 | Langerhans cell histiocytosis | KG + DL |
| 26 | atrichia with papular lesions | KG + DL |
| 27 | thymic epithelial neoplasm | KG + DL |
| 28 | nodular lymphocyte predominant Hodgkin lymphoma | KG + DL |
| 29 | acute biphenotypic leukemia | KG + DL |
| 30 | B-cell prolymphocytic leukemia | KG + DL |
| 31 | classic Hodgkin lymphoma | KG + DL |
| 32 | plasma cell neoplasm | KG + DL |
| 33 | ectodermal dysplasia and immunodeficiency | KG + DL |
| 34 | classic Hodgkin lymphoma, lymphocyte-depleted type | KG + DL |
| 35 | indolent plasma cell myeloma | KG + DL |
| 36 | Hodgkin’s lymphoma, lymphocytic depletion | KG + DL |
| 37 | histiocytic and dendritic cell neoplasm | KG + DL |
| 38 | classic Hodgkin lymphoma, mixed cellularity type | KG + DL |
| 39 | Hodgkin’s paragranuloma | KG + DL |
| 40 | obsolete Hodgkin’s granuloma | KG + DL |
| 41 | childhood carcinoid tumor | KG + DL |
| 42 | childhood ependymoma | KG + DL |
| 43 | childhood germ cell tumor | KG + DL |
| 44 | optic nerve glioma | KG + DL |
| 45 | neonatal jaundice | KG + DL |
| 46 | childhood mediastinal neurogenic neoplasm | KG + DL |
| 47 | fetal akinesia-cerebral and retinal hemorrhage syndrome | KG + DL |
| 48 | marginal zone lymphoma | KG + DL |
| 49 | secondary interstitial lung disease in childhood and adulthood associated with a systemic vasculitis | KG + DL |
| 50 | childhood choroid plexus neoplasm | KG + DL |
(Showing top 50 of 100 predictions)
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.